TWI796377B - 共晶體、其藥物組合物以及涉及其的治療方法 - Google Patents
共晶體、其藥物組合物以及涉及其的治療方法 Download PDFInfo
- Publication number
- TWI796377B TWI796377B TW107139079A TW107139079A TWI796377B TW I796377 B TWI796377 B TW I796377B TW 107139079 A TW107139079 A TW 107139079A TW 107139079 A TW107139079 A TW 107139079A TW I796377 B TWI796377 B TW I796377B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- degrees
- formula
- crystal
- cancer
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580501P | 2017-11-02 | 2017-11-02 | |
| US62/580,501 | 2017-11-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201930285A TW201930285A (zh) | 2019-08-01 |
| TWI796377B true TWI796377B (zh) | 2023-03-21 |
Family
ID=64572453
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107139079A TWI796377B (zh) | 2017-11-02 | 2018-11-02 | 共晶體、其藥物組合物以及涉及其的治療方法 |
| TW112106677A TWI839131B (zh) | 2017-11-02 | 2018-11-02 | 共晶體、其藥物組合物以及涉及其的治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112106677A TWI839131B (zh) | 2017-11-02 | 2018-11-02 | 共晶體、其藥物組合物以及涉及其的治療方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11345677B2 (enExample) |
| EP (1) | EP3704101B1 (enExample) |
| JP (3) | JP7335877B2 (enExample) |
| KR (1) | KR102731624B1 (enExample) |
| CN (2) | CN118359585A (enExample) |
| AU (3) | AU2018360827B2 (enExample) |
| CA (1) | CA3081535A1 (enExample) |
| DK (1) | DK3704101T3 (enExample) |
| EA (1) | EA202091112A1 (enExample) |
| ES (1) | ES3075257T3 (enExample) |
| FI (1) | FI3704101T3 (enExample) |
| HR (1) | HRP20260783T1 (enExample) |
| IL (2) | IL274123B2 (enExample) |
| LT (1) | LT3704101T (enExample) |
| MA (1) | MA50526B1 (enExample) |
| MX (2) | MX2020004513A (enExample) |
| PH (1) | PH12020550462A1 (enExample) |
| PT (1) | PT3704101T (enExample) |
| RS (1) | RS68236B1 (enExample) |
| SG (1) | SG11202003612VA (enExample) |
| SI (1) | SI3704101T1 (enExample) |
| SM (1) | SMT202600262T1 (enExample) |
| TW (2) | TWI796377B (enExample) |
| UA (1) | UA127380C2 (enExample) |
| WO (1) | WO2019090059A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085832A1 (en) * | 2019-11-22 | 2020-03-19 | Agios Pharmaceuticals, Inc. | Deuterated analogs of an organic compound |
| TW202227446A (zh) | 2020-08-12 | 2022-07-16 | 美商施維雅製藥有限公司 | 有機化合物之固態形式 |
| US20230346789A1 (en) * | 2022-03-31 | 2023-11-02 | Msd International Gmbh | Methods of treating enhancing brain tumors using combination therapy |
| AR133332A1 (es) | 2023-07-25 | 2025-09-17 | Servier Lab | Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos |
| CN121843929A (zh) * | 2023-09-18 | 2026-04-10 | 贝达药业股份有限公司 | 突变型idh抑制剂化合物及其盐的固体形式 |
| EP4538262A1 (en) | 2023-10-12 | 2025-04-16 | Sandoz Ag | Cocrystals of vorasidenib |
| US20250257050A1 (en) | 2024-02-09 | 2025-08-14 | Les Laboratoires Servier | Process for the preparation of vorasidenib |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015003640A1 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013010564B1 (pt) * | 2010-11-01 | 2021-09-21 | Celgene Car Llc | Compostos heterocíclicos e composições compreendendo os mesmos |
| SMT201800334T1 (it) | 2012-01-06 | 2018-09-13 | Agios Pharmaceuticals Inc | Composti terapeuticamente attivi e loro metodi di utilizzo |
-
2018
- 2018-11-02 UA UAA202003279A patent/UA127380C2/uk unknown
- 2018-11-02 EA EA202091112A patent/EA202091112A1/ru unknown
- 2018-11-02 IL IL274123A patent/IL274123B2/en unknown
- 2018-11-02 CA CA3081535A patent/CA3081535A1/en active Pending
- 2018-11-02 US US16/760,520 patent/US11345677B2/en active Active
- 2018-11-02 ES ES18812419T patent/ES3075257T3/es active Active
- 2018-11-02 WO PCT/US2018/058930 patent/WO2019090059A1/en not_active Ceased
- 2018-11-02 MA MA50526A patent/MA50526B1/fr unknown
- 2018-11-02 AU AU2018360827A patent/AU2018360827B2/en active Active
- 2018-11-02 CN CN202410230044.7A patent/CN118359585A/zh active Pending
- 2018-11-02 JP JP2020524501A patent/JP7335877B2/ja active Active
- 2018-11-02 SG SG11202003612VA patent/SG11202003612VA/en unknown
- 2018-11-02 KR KR1020207015661A patent/KR102731624B1/ko active Active
- 2018-11-02 CN CN201880079771.0A patent/CN111527076B/zh active Active
- 2018-11-02 TW TW107139079A patent/TWI796377B/zh active
- 2018-11-02 IL IL305426A patent/IL305426B2/en unknown
- 2018-11-02 SI SI201831324T patent/SI3704101T1/sl unknown
- 2018-11-02 EP EP18812419.2A patent/EP3704101B1/en active Active
- 2018-11-02 FI FIEP18812419.2T patent/FI3704101T3/fi active
- 2018-11-02 DK DK18812419.2T patent/DK3704101T3/da active
- 2018-11-02 RS RS20260702A patent/RS68236B1/en unknown
- 2018-11-02 LT LTEPPCT/US2018/058930T patent/LT3704101T/lt unknown
- 2018-11-02 PT PT188124192T patent/PT3704101T/pt unknown
- 2018-11-02 SM SM20260262T patent/SMT202600262T1/it unknown
- 2018-11-02 HR HRP20260783TT patent/HRP20260783T1/hr unknown
- 2018-11-02 MX MX2020004513A patent/MX2020004513A/es unknown
- 2018-11-02 TW TW112106677A patent/TWI839131B/zh active
-
2020
- 2020-04-22 PH PH12020550462A patent/PH12020550462A1/en unknown
- 2020-07-13 MX MX2022014792A patent/MX2022014792A/es unknown
-
2022
- 2022-04-19 US US17/723,666 patent/US11851417B2/en active Active
-
2023
- 2023-04-24 JP JP2023070786A patent/JP7499377B2/ja active Active
- 2023-11-08 US US18/504,859 patent/US12679820B2/en active Active
-
2024
- 2024-05-14 AU AU2024203186A patent/AU2024203186B2/en active Active
- 2024-06-03 JP JP2024090124A patent/JP7780576B2/ja active Active
-
2026
- 2026-07-13 AU AU2026205552A patent/AU2026205552A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015003640A1 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7499377B2 (ja) | 共結晶、その医薬組成物、およびそれを伴う治療方法 | |
| WO2020092906A1 (en) | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof | |
| US20250041283A1 (en) | Cocrystal of an idh1 inhibitor, process of preparation thereof, pharmaceutical compositions thereof, and methods of treatment involving the same | |
| US20250034109A1 (en) | Salts, cocrystals, pharmaceutical compositions thereof, and methods of treatment involving the same | |
| WO2021102221A1 (en) | Deuterated analogs of an idh1 inhibitor | |
| BR112020008598B1 (pt) | Cocristal, composição farmacêutica e usos de um cocristal ou de uma composição farmacêutica | |
| EA048730B1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| EA042081B1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение |